Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.
Sloop KW, Cox AL, Wainscott DB, White A, Droz BA, Stutsman C, Showalter AD, Suter TM, Dunbar JD, Snider BM, O'Farrell LS, Hewitt N, Ruble JC, Padgett LR, Woerly EM, Peterson JA, Coskun T, Liu Z, Coutant DE, Ai M, Emmerson PJ, Sangwung P, Willard FS. Sloop KW, et al. Among authors: coutant de. Sci Transl Med. 2024 Dec 18;16(778):eadp5765. doi: 10.1126/scitranslmed.adp5765. Epub 2024 Dec 18. Sci Transl Med. 2024. PMID: 39693407
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union.
Byrd RA, Owens RA, Blackbourne JL, Coutant DE, Farmen MW, Michael MD, Moyers JS, Schultze AE, Sievert MK, Tripathi NK, Vahle JL. Byrd RA, et al. Among authors: coutant de. Regul Toxicol Pharmacol. 2017 Aug;88:56-65. doi: 10.1016/j.yrtph.2017.05.013. Epub 2017 May 17. Regul Toxicol Pharmacol. 2017. PMID: 28526658
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study.
Datta-Mannan A, Regev A, Coutant DE, Dropsey AJ, Foster J, Jones S, Poorbaugh J, Schmitz C, Wang E, Woodman ME. Datta-Mannan A, et al. Among authors: coutant de. Clin Pharmacol Ther. 2024 May;115(5):1152-1161. doi: 10.1002/cpt.3185. Epub 2024 Jan 31. Clin Pharmacol Ther. 2024. PMID: 38294091 Clinical Trial.
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
Leohr J, Dellva MA, LaBell E, Coutant DE, Arrubla J, Plum-Mörschel L, Zijlstra E, Fukuda T, Hardy T. Leohr J, et al. Among authors: coutant de. Diabetes Obes Metab. 2024 Jan;26(1):215-223. doi: 10.1111/dom.15307. Epub 2023 Oct 9. Diabetes Obes Metab. 2024. PMID: 37814517 Clinical Trial.
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.
Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C, Bue-Valleskey J, Zhang Q, Dellva MA, Leohr J. Heise T, et al. Diabetes Obes Metab. 2020 Oct;22(10):1789-1798. doi: 10.1111/dom.14094. Epub 2020 Jun 18. Diabetes Obes Metab. 2020. PMID: 32436641 Free PMC article. Clinical Trial.
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study.
Leohr J, Dellva MA, Coutant DE, LaBell E, Heise T, Andersen G, Zijlstra E, Hermanski L, Nosek L, Linnebjerg H. Leohr J, et al. Among authors: coutant de. Clin Pharmacokinet. 2020 Dec;59(12):1601-1610. doi: 10.1007/s40262-020-00901-2. Clin Pharmacokinet. 2020. PMID: 32468448 Free PMC article. Clinical Trial.
24 results